(4) Clinical inflammatory bowel disease re-
search, including clinical studies and treatment 
trials. 
(5) Expansion of the Institute’s Inflammatory 
Bowel Disease Centers program with a focus on pe-
diatric research. 
(6) Other research initiatives identified by the 
scientific document entitled ‘‘Challenges in Inflam-
matory Bowel Disease’’ and the research agenda for 
pediatric gastroenterology, hepatology, and nutrition 
entitled ‘‘Chronic Inflammatory Bowel Disease’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.— 
(1) IN GENERAL.—For the purpose of carrying 
out subsection (a), there are authorized to be appro-
priated 
$80,000,000 
for 
fiscal 
year 
2008, 
$90,000,000 for fiscal year 2009, and $100,000,000 
for fiscal year 2010. 
(2) RESERVATION.—Of the amounts authorized 
to be appropriated under paragraph (1), not more 
than 20 percent shall be reserved for the training of 
qualified health professionals in biomedical research 
focused on inflammatory bowel disease, including pe-
diatric investigators. 
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1113.IH
H1113
mstockstill on PROD1PC66 with BILLS
SEC. 4. AMENDMENT TO THE PUBLIC HEALTH SERVICE 
ACT. 
Part B of title III of the Public Health Service Act 
(42 U.S.C. 243 et seq.) is amended by inserting after sec-
tion 317S the following: 
‘‘SEC. 317T. PEDIATRIC INFLAMMATORY BOWEL DISEASE 
REGISTRY. 
‘‘(a) ESTABLISHMENT.— 
‘‘(1) IN GENERAL.—Not later than 6 months 
after the receipt of the report described in sub-
section (b)(3), the Secretary, acting through the Di-
rector of the Centers for Disease Control and Pre-
vention and in consultation with a national voluntary 
patient organization with experience serving the pop-
ulation of individuals with pediatric inflammatory 
bowel disease and organizations representing physi-
cians and other health professionals specializing in 
the treatment of this population, shall— 
‘‘(A) develop a system to collect data on 
pediatric IBD; and 
‘‘(B) establish a national registry, to be 
known as the National Pediatric IBD Registry, 
for the collection and storage of such data. 
‘‘(2) PURPOSES OF REGISTRY.—The National 
Pediatric IBD Registry— 
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H1113.IH
H1113
mstockstill on PROD1PC66 with BILLS
‘‘(A) shall include a population-based reg-
istry of cases of pediatric IBD in the United 
States; 
‘‘(B) shall be used to gather data con-
cerning— 
‘‘(i) pediatric IBD, including the inci-
dence and prevalence of pediatric IBD in 
the United States; 
‘‘(ii) the genetic and environmental 
factors that may be associated with pedi-
atric IBD; 
‘‘(iii) the age, race or ethnicity, gen-
der, and family history of individuals who 
are diagnosed with pediatric IBD; 
‘‘(iv) treatment approaches and out-
comes; and 
‘‘(v) other matters as recommended 
by the Advisory Committee established 
under subsection (b); and 
‘‘(C) shall be used to establish a secure 
method to put patients in contact with sci-
entists studying the environmental and genetic 
causes of pediatric IBD or conducting clinical 
trials on pediatric IBD. 
‘‘(b) ADVISORY COMMITTEE.— 
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H1113.IH
H1113
mstockstill on PROD1PC66 with BILLS
‘‘(1) ESTABLISHMENT.—Not later than 90 days 
after the date of the enactment of this section, the 
Secretary, acting through the Director of the Cen-
ters for Disease Control and Prevention, shall estab-
lish a committee to be known as the Advisory Com-
mittee on Pediatric Inflammatory Bowel Disease. 
‘‘(2) MEMBERS.—The members of the Advisory 
Committee shall be appointed by the Secretary, act-
ing through the Director of the Centers for Disease 
Control and Prevention, and shall include at least 
one representative of each of the following: 
‘‘(A) A national voluntary patient organi-
zation that focuses on pediatric IBD and has 
demonstrated experience in pediatric IBD re-
search, care, and patient services. 
‘‘(B) A professional pediatric gastro-
enterology organization with expertise in pedi-
atric research, care, and patient services. 
‘‘(C) The National Institutes of Health. 
‘‘(D) If recommended by the Director of 
the National Institutes of Health— 
‘‘(i) the National Institute of Diabetes 
and Digestive and Kidney Diseases; 
‘‘(ii) the National Institute of Allergy 
and Infectious Diseases; 
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H1113.IH
H1113
mstockstill on PROD1PC66 with BILLS
‘‘(iii) the National Institute of Child 
Health and Human Development; and 
‘‘(iv) any other appropriate national 
research institute or national center. 
‘‘(E) The Centers for Disease Control and 
Prevention. 
‘‘(F) Pediatric gastroenterologists and 
other clinicians who have experience with data 
registries. 
‘‘(G) Epidemiologists who have experience 
with data registries. 
‘‘(H) Geneticists or experts in genetics who 
have experience with the genetics of pediatric 
IBD. 
‘‘(I) Other individuals with an interest in 
developing and maintaining the National Pedi-
atric IBD Registry. 
‘‘(3) STUDY.—The Advisory Committee shall 
conduct a study and make recommendations on— 
‘‘(A) the development and maintenance of 
the National Pediatric IBD Registry; 
‘‘(B) the type of information to be col-
lected and stored in the Registry; 
‘‘(C) the manner in which such data is to 
be collected; and 
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H1113.IH
H1113
mstockstill on PROD1PC66 with BILLS
‘‘(D) the use and availability of such data 
including guidelines for such use. 
‘‘(4) REPORT.—Not later than 6 months after 
the date on which the Advisory Committee is estab-
lished, the Advisory Committee shall submit a report 
to the Secretary and the Congress on the results of 
the study conducted under paragraph (3), including 
the recommendations of the Advisory Committee 
with respect to such results. 
‘‘(c) GRANTS.—The Secretary, acting through the 
Director of the Centers for Disease Control and Preven-
tion, may award grants to, and enter into contracts and 
cooperative agreements with, public or private nonprofit 
entities for the collection, analysis, and reporting of data 
on pediatric IBD. 
‘‘(d) COORDINATION WITH EXISTING REGISTRIES 
AND DATA REPOSITORIES.— 
‘‘(1) IN
GENERAL.—In establishing the Na-
tional Pediatric IBD Registry under subsection (a), 
the Secretary, acting through the Director of the 
Centers for Disease Control and Prevention, shall 
identify, build upon, expand, and coordinate among 
existing public and private surveillance systems, and 
registries concerning pediatric IBD. 
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H1113.IH
H1113
mstockstill on PROD1PC66 with BILLS
‘‘(2) COORDINATION WITH NIH.—The Secretary 
shall ensure that epidemiological and other types of 
information obtained under subsection (a) are made 
available to the National Institutes of Health. 
‘‘(e) DEFINITIONS.—In this section: 
‘‘(1) The term ‘Advisory Committee’ means the 
Advisory Committee on Pediatric Inflammatory 
Bowel Disease established under subsection (b). 
‘‘(2) The terms ‘national research institute’ and 
‘national center’ have the meanings given to those 
terms in section 401(g). 
‘‘(3) The term ‘national voluntary patient orga-
nization’ means a national non-profit patient organi-
zation with chapters in States throughout the 
United States. 
‘‘(4) The term ‘pediatric IBD’ means pediatric 
inflammatory bowel disease. 
‘‘(f) AUTHORIZATION
OF
APPROPRIATIONS.—To 
carry out this section, there are authorized to be appro-
priated $5,000,000 for fiscal year 2008 and such sums 
as may be necessary for each of fiscal years 2009 and 
2010.’’. 
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H1113.IH
H1113
mstockstill on PROD1PC66 with BILLS
SEC. 5. CENTERS FOR DISEASE CONTROL AND PREVEN-
TION; NATIONAL INFLAMMATORY BOWEL DIS-
EASE ACTION PLAN. 
(a) IN GENERAL.— 
(1) PREPARATION OF PLAN.—The Director of 
the Centers for Disease Control and Prevention, in 
consultation with the inflammatory bowel disease 
community, shall prepare a comprehensive plan to 
address the burden of inflammatory bowel disease in 
both adult and pediatric populations (which plan 
shall be designated by the Director as the ‘‘National 
Inflammatory Bowel Disease Action Plan’’). 
(2) REPORT TO CONGRESS.—Not later than 12 
months after the date of the enactment of this Act, 
the Director of the Centers for Disease Control and 
Prevention shall submit the Plan referred to in para-
graph (1) to the Committee on Energy and Com-
merce and the Committee on Appropriations of the 
House of Representatives and to the Committee on 
Health, Education, Labor and Pensions and the 
Committee on Appropriations of the Senate. 
(b) CONTENT.— 
(1) IN GENERAL.—The National Inflammatory 
Bowel Disease Action Plan shall address strategies 
for determining the unique demographic, geographic, 
and environmental-exposure characteristics of the in-
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H1113.IH
H1113
mstockstill on PROD1PC66 with BILLS